Assessment of Adherence, Effectiveness and Convenience of Rebif Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart.
Phase of Trial: Phase IV
Latest Information Update: 23 Jun 2015
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SMART
- Sponsors Merck KGaA
- 23 Jun 2015 Results (follow-up of German cohort) presented at the 1st Congress of the European Academy of Neurology.
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 19 Sep 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History